Stockscreener 앱 받기
22.64
0.79%
-0.18
시간 외 거래:
22.58
-0.06
-0.27%
전일 마감가:
$22.82
열려 있는:
$22.83
하루 거래량:
340.58K
Relative Volume:
0.60
시가총액:
$890.84M
수익:
$734.86M
순이익/손실:
$5.14M
주가수익비율:
181.12
EPS:
0.125
순현금흐름:
$132.71M
1주 성능:
-3.33%
1개월 성능:
+0.00%
6개월 성능:
-14.73%
1년 성능:
-7.18%
1일 변동 폭
$22.57
$23.80
1주일 범위
$22.56
$24.03
52주 변동 폭
$18.80
$27.64
Pacira Biosciences Inc Stock (PCRX) Company Profile
명칭
Pacira Biosciences Inc
전화
650-242-8052
주소
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Compare PCRX vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
22.64 | 894.77M | 734.86M | 5.14M | 132.71M | 0.125 |
TAK
Takeda Pharmaceutical Co Adr
|
15.42 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.87 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.56 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.26 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
551.47 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Equal Weight |
| 2025-11-17 | 개시 | H.C. Wainwright | Buy |
| 2025-07-25 | 업그레이드 | Truist | Hold → Buy |
| 2025-01-30 | 업그레이드 | Truist | Sell → Hold |
| 2024-08-13 | 다운그레이드 | Truist | Buy → Sell |
| 2024-08-12 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2024-08-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-03-07 | 재개 | JP Morgan | Overweight |
| 2023-12-20 | 개시 | Raymond James | Outperform |
| 2023-08-03 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | 재개 | Wedbush | Outperform |
| 2022-10-21 | 재개 | Jefferies | Buy |
| 2022-01-03 | 재개 | JP Morgan | Overweight |
| 2021-07-26 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-04-21 | 재개 | JP Morgan | Neutral |
| 2021-04-09 | 개시 | Berenberg | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-02-11 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | 재확인 | Needham | Buy |
| 2020-05-27 | 개시 | Guggenheim | Neutral |
| 2020-04-07 | 개시 | Northland Capital | Outperform |
| 2020-03-20 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-24 | 개시 | SunTrust | Buy |
| 2020-01-23 | 개시 | SunTrust | Buy |
| 2019-11-06 | 개시 | BTIG Research | Buy |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-05-06 | 업그레이드 | Mizuho | Underperform → Neutral |
| 2019-05-02 | 업그레이드 | Stifel | Sell → Hold |
| 2019-02-01 | 다운그레이드 | Mizuho | Neutral → Underperform |
| 2018-08-06 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | 재확인 | H.C. Wainwright | Buy |
| 2018-03-21 | 재확인 | Mizuho | Neutral |
| 2018-02-16 | 다운그레이드 | Needham | Buy → Hold |
| 2018-01-19 | 개시 | Seaport Global Securities | Buy |
| 2018-01-04 | 재확인 | Canaccord Genuity | Buy |
| 2018-01-03 | 개시 | Leerink Partners | Mkt Perform |
모두보기
Pacira Biosciences Inc 주식(PCRX)의 최신 뉴스
Osteoarthritis Market Expected to Showcase Moderate Growth at a CAGR of 3% During the Forecast Period (2026–2036) Driven by Emerging Therapies and Rising Disease Burden | DelveInsight - GlobeNewswire Inc.
Insider Sell: Lauren Riker Sells Shares of Pacira BioSciences In - GuruFocus
Pacira BioSciences SVP Lauren Riker sells $143,702 in stock By Investing.com - Investing.com India
Pacira BioSciences SVP Lauren Riker sells $143,702 in stock - Investing.com
Pacira BioSciences (PCRX) director receives RSU and stock option grants - Stock Titan
Pacira (PCRX) director Mark Froimson receives new stock and option grants - Stock Titan
PCRX (NASDAQ) shows 2,876 and 6,163 restricted shares vesting - Stock Titan
Pacira BioSciences Announces Election of All Director Nominees at 2026 Annual Meeting and Highlights Non-Opioid Pain Therapies Strategy – Minichart - Minichart
Pacira BioSciences (NASDAQ:PCRX) Stock Crosses Below 50 Day Moving AverageShould You Sell? - MarketBeat
Pacira (NASDAQ: PCRX) investors reelect board nominees and add 800,000 ESPP shares - Stock Titan
[144] Pacira BioSciences, Inc. SEC Filing - Stock Titan
Biotech company shareholders elect Chris Christie in rejecting activist investor's slate - The Business Journals
Pacira BioSciences Announces Stockholders Have Elected All Three of the Company's Director Nominees at Annual Meeting - Yahoo Finance
Pacira BioSciences (PCRX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Pacira shareholders lobbied by hedge fund board nominees - MSN
Pacira BioSciences CAO Kristen Williams sells $228,467 in stock By Investing.com - Investing.com Australia
Technical Reactions to PCRX Trends in Macro Strategies - Stock Traders Daily
Pacira BioSciences CAO Kristen Williams sells $228,467 in stock - Investing.com
Pacira (PCRX) SVP has 3,187 shares withheld for tax obligations - Stock Titan
Pacira BioSciences (NASDAQ: PCRX) CMO has 4,728 shares withheld for taxes - Stock Titan
Pacira (PCRX) CAO sells 10,259 shares under pre-set 10b5-1 trading plan - Stock Titan
Three major proxy firms side with Pacira in boardroom showdown - Stock Titan
Pacira BioSciences Reminds Stockholders to Vote the BLUE Proxy Card "FOR" the Election of the Company's Highly Qualified Nominees Ahead of its Annual Meeting - Yahoo Finance
Pacira Stock Waits for June 9 Board Fight - Bez Kabli
Pacira BioSciences' CFO Sold 12,941 Shares for $326,000 Before Its Q1 Earnings Release - AOL.com
PCRX DEADLINE NOTICE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Pacira BioSciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 14 Deadline in Securities Class ActionPCRX - TMX Newsfile
Pacira Biosciences Inc (NASDAQ:PCRX) Emerges as a Deep Value Opportunity with Strong Financial Health - ChartMill
Press Release: Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees - Moomoo
Pacira BioSciences, Inc.Common Stock (NQ: PCRX - FinancialContent
Pacira (PCRX): Glass Lewis Recommends Stockholder Votes - GuruFocus
Glass Lewis Backs Pacira BioSciences Director Slate Ahead of Key VoteRevenue Guidance Update - The Legal Advocate
[DFAN14A] Pacira BioSciences, Inc. SEC Filing - Stock Titan
Pacira Biosciences IncProxy Advisory Firm Glass Lewis Recommends Stockholders Vote "For" All Of Pacira's Director Nominees - TradingView
Pacira BioSciences, Inc. Receives Glass Lewis Endorsement for Director Nominees Ahead of 2026 Annual Meeting - Quiver Quantitative
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote 'FOR” All of Pacira’s Director Nominees - The Manila Times
Leading Independent Proxy Advisory Firm Glass Lewis - GlobeNewswire
DOMA Perpetual Capital Provides Information to Shareholders of Pacira BioSciences - marketscreener.com
DOMA PERPETUAL CAPITAL MANAGEMENT QUESTIONS WHY SHAREHOLDERS SHOULD VOTE TO CONTINUE WITH A BOARD THAT HAS OVERSEEN A DECADE OF VALUE DESTRUCTION - Quantisnow
Pacira study links EXPAREL to lower opioid use after surgery - Investing.com UK
Considering Pacira Biosciences Inc (PCRX) Stock After Q1 Report? Check the Details - Yahoo Finance
Pacira BioSciences urges shareholders to suppor... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
Pacira (PCRX) Highlights Positive Study Outcomes on Exparel Usage - GuruFocus
Pacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company’s Strategic Direction and Highly Qualified Nominees - The Manila Times
Pacira BioSciences Mails Letter to Stockholders Reiterating - GlobeNewswire
symbol__ Stock Quote Price and Forecast - CNN
Pacira BioSciences Says Exparel Linked to Lower Opioid Use, Healthcare Costs - Moomoo
Pacira study links EXPAREL to lower opioid use after surgery By Investing.com - Investing.com Australia
Pacira BioSciences Reports Real-World Study Showing EXPAREL® Use Was Associated with Reduced Opioid Use and Healthcare Costs in Patients Undergoing Total Shoulder Arthroplasty - The Manila Times
Pacira BioSciences Reports Real-World Study Showing - GlobeNewswire
Pacira (PCRX) Addresses Stockholder Concerns Over Misleading Cla - GuruFocus
Pacira BioSciences Sets the Record Straight Regarding DOMA’s Misleading Statements About Pacira’s Intellectual Property Strategy - The Manila Times
Pacira Biosciences Inc (PCRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.95%
1.13%
자본화:
|
볼륨(24시간):